文献速递肝肾功能剂量调整特殊人群用药

CFTR调节剂在特殊囊性纤维化人群中的药代动力学:系统综述

Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review.
PubMed 文献 · Clin Pharmacokinet · 2025-05-21

该系统综述检索PubMed和Embase,评估ivacaftor、tezacaftor、elexacaftor和lumacaftor在特殊囊性纤维化人群中的药代动力学。轻中度肝损伤患者暴露量无实质升高,胰腺外分泌功能不全不影响药代动力学,儿童因按体重给药暴露水平高于成人。重度肝损伤、儿童肝损伤及妊娠哺乳人群证据不足。

要点

  • 轻中度肝损伤不显著升高CFTR调节剂暴露量
  • 胰腺外分泌功能不全对成人CFTR调节剂药代动力学无影响
  • 儿童按体重给药暴露水平高于成人

核心结论

  • CFTR调节剂在轻中度肝损伤成人和儿童中研究较充分,但重度肝损伤、儿童肝损伤及妊娠哺乳人群证据不足。

研究设计与样本

  • 系统综述,检索PubMed和Embase(截至2024年6月20日),纳入提供CFTR调节剂药代动力学或暴露信息的研究。

主要发现

  • 轻中度肝损伤囊性纤维化患者CFTR调节剂暴露量较无肝损伤或健康个体无实质升高。
  • 胰腺外分泌功能不全对成人囊性纤维化患者CFTR调节剂药代动力学无影响。
  • 儿童囊性纤维化患者因按体重(mg/kg)接受更高剂量,CFTR调节剂暴露水平高于成人。

临床怎么用

  • 轻中度肝损伤成人及胰腺外分泌功能不全成人可按常规剂量使用CFTR调节剂。
  • 儿童按体重给药时需关注其暴露水平高于成人,确保疗效同时监测安全性。
  • 重度肝损伤(Child-Pugh C级)、儿童肝损伤及妊娠哺乳患者缺乏充分药代动力学数据,用药需谨慎。

局限性

  • 重度肝损伤(Child-Pugh C级)成人、儿童囊性纤维化相关肝损伤及妊娠哺乳人群的药代动力学证据缺乏。
  • 现有研究在成人和轻中度肝损伤及儿童中较充分,其他特殊人群数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Following the development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators (ivacaftor, tezacaftor, elexacaftor, and lumacaftor), the prognosis for people diagnosed with cystic fibrosis (pwCF) has improved. Understanding the pharmacokinetics (PK) of CFTR modulators is crucial to provide optimal care, particularly in special cystic fibrosis (CF) populations such as pwCF with hepatic impairment, pancreatic insufficiency, those who are pregnant or lactating, or who are children. We aim to provide an overview of the PK of CFTR modulators in these populations. METHODS: A systematic literature search was carried out in PubMed and Embase on 20 June 2024. Studies were considered relevant when information on PK or exposure of CFTR-modulating drugs was available. RESULTS: PwCF with mild/moderate hepatic impairment do not exhibit substantially higher exposure to CFTR modulators compared with those without liver involvement or healthy individuals. Similarly, exocrine pancreatic insufficiency has no effect on the PK of CFTR modulators in adult pwCF. In contrast, pediatric pwCF are exposed to higher levels of CFTR modulators relative to adults, as children receive higher weight-based doses (mg/kg) to ensure equivalent therapeutic efficacy. CONCLUSIONS: The PK of CFTR modulators have been more extensively studied in adults, pwCF with mild/moderate hepatic impairment, and children. However, ensuring adequate dosing remains challenging. Knowledge gaps persist for adults with severe hepatic impairment (Child-Pugh Class C), children with CF-induced hepatic impairment, and pregnant or lactating pwCF. Future research addressing these gaps, through incorporating routine clinical data, is crucial for improving clinical guidelines and optimizing dosing regimens, thereby advancing towards evidence-based utilization of CFTR modulators.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Elzinga FA, Malik PRV, Akkerman OW, et al. Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review. Clin Pharmacokinet. 2025. PMID: 40399734. doi:10.1007/s40262-025-01507-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。